is the bispecific dart, flotetuzumab, effective as salvage therapy in patients with r/r aml?
Published 4 years ago • 186 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
3:14
does the bispecific vibecotamab hold promise for r/r aml?
-
1:23
improving the efficacy of bispecific antibodies in aml
-
1:02
bispecific agents: the future of aml and mds treatment?
-
1:36
bispecific antibodies for r/r aml: ongoing clinical trials
-
10:15
quizartinib for flt3-mutated aml
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
1:40
sf3b1 as therapeutic target in flt3/itd positive aml
-
4:09
quantum-r: quizartinib looks promising for flt3-itd mutated aml
-
1:54
the important role of bispecific antibodies in the future treatment of r/r dlbcl
-
1:56
cevostamab (bfcr4350a): a novel bispecific antibody in r/r myeloma therapy
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:05
t-cell evolution in aml and its impact on the efficacy of bispecific antibodies
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
1:10
how bispecific antibodies contribute to t-cell activation in aml
-
57:20
know your myeloma immunotherapy: bispecific antibodies with dr. cesar rodriguez
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
2:52
results of trial of vadastuximab talirine plus hypomethylating agents in aml